Gregory Norden sold $1.2M of RPRX
director at Royalty Pharma plc. 33,500 shares at an average of $36.23, traded Aug 11, 2025, filed Aug 11, 2025.
Score components
- +15RoleDirector
- +25Trade size$1.2M at market
- +5Share of holdings soldSold 15% of holdings
- 0ClusterNo other insider selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001802768-25-000107, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 8, 2025 | CConversion Class A Ordinary Shares | +144,660 | $0.00 | $0 | 228,348 | Aug 11, 2025 |
| Aug 11, 2025 | SOpen-market sale Class A Ordinary Shares | -33,500 | $36.23 | $1.2M | 194,848 | Aug 11, 2025 |
| Aug 8, 2025 | CConversion LP interests in RPI US Partners 2019, LPderivative | -14,466 | $0.00 | $0 | 0 | Aug 11, 2025 |
Related signals
Other insiders at Royalty Pharma plc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | Royalty Pharma plc | Marshall Urist EVP, Research & Investments | $236k 4,126 shares | -100% | |
| 36Weak | Royalty Pharma plc | Marshall Urist EVP, Research & Investments | $239k 4,126 shares | -50% | |
| 43Moderate | Royalty Pharma plc | Christopher Hite EVP & Chairman, Partnering | $5.9M 100,000 shares | -27% | |
| 47Moderate | Royalty Pharma plc | Terrance P. Coyne EVP & CFO | $3.5M 64,399 shares | -100% | |
| 47Moderate | Royalty Pharma plc | Terrance P. Coyne EVP & CFO | $1.7M 34,791 shares | -106% | |
| 47Moderate | Royalty Pharma plc | Terrance P. Coyne EVP & CFO | $1.7M 34,791 shares | -79% | |
| 37Weak | Royalty Pharma plc | Terrance P. Coyne EVP & CFO | $1.6M 34,791 shares | -35% | |
| 37Weak | Royalty Pharma plc | Terrance P. Coyne EVP & CFO | $1.6M 34,791 shares | -26% | |
| 32Weak | Royalty Pharma plc | Terrance P. Coyne EVP & CFO | $1.6M 34,791 shares | -21% | |
| 55Moderate | Royalty Pharma plc | Terrance P. Coyne EVP & CFO | $10M 243,541 shares | -62% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.